Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company's two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may enhance outcomes over currently available treatment options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/18 | $100,000,000 |
Cormorant Asset Management Deerfield Management Company, L.P. Fidelity Investments Hillhouse Capital Group NS Investment OrbiMed Advisors Sirona Capital SR One The Column Group Third Rock Ventures University of California Venrock | undisclosed |
